Athenex Inc (NASDAQ:ATNX) has been given a consensus broker rating score of 2.00 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. Athenex’s rating score has declined by 33.3% from three months ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 1-year consensus target price of $25.73 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 98 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently issued reports on ATNX shares. Credit Suisse Group started coverage on Athenex in a research report on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Royal Bank Of Canada started coverage on Athenex in a research report on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. Laidlaw started coverage on Athenex in a research report on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Finally, J P Morgan Chase & Co started coverage on Athenex in a research report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock.

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System acquired a new stake in Athenex during the third quarter worth about $198,000. Bank of New York Mellon Corp acquired a new stake in Athenex during the second quarter worth about $240,000. Tudor Investment Corp ET AL acquired a new stake in Athenex during the second quarter worth about $320,000. Schwab Charles Investment Management Inc. acquired a new stake in Athenex during the third quarter worth about $524,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Athenex during the second quarter worth about $601,000. 2.93% of the stock is currently owned by institutional investors.

Athenex (ATNX) opened at $16.62 on Tuesday. Athenex has a 1-year low of $11.21 and a 1-year high of $20.79.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/zacks-athenex-inc-atnx-given-consensus-recommendation-of-buy-by-analysts.html.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.